WO1997025421B1 - PROTEIN INDUCED BY DEPRENYL$m(3) - Google Patents
PROTEIN INDUCED BY DEPRENYL$m(3)Info
- Publication number
- WO1997025421B1 WO1997025421B1 PCT/EP1996/005800 EP9605800W WO9725421B1 WO 1997025421 B1 WO1997025421 B1 WO 1997025421B1 EP 9605800 W EP9605800 W EP 9605800W WO 9725421 B1 WO9725421 B1 WO 9725421B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dip
- activity
- compound
- neural
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
We have found that Deprenyl® induces a novel polypeptide in neural cells. This polypeptide has the structure given in SEQ ID No. 1 and is referred to herein as DIP 1 (Deprenyl® Induced Protein 1).
Claims
1. Deprenyl®-induced protein 1 (DIP 1 ) having the sequence represented in SEQ ID NO:1 and functional derivatives thereof.
2. The protein according to claim 1 , the functional derivative thereof or a modulator of DIP 1 activity for use in preventing or alleviating apoptotic cell death in neural disease.
3. A method for screening a compound or a combination of compounds for an ability to rescue neural cells from apoptosis comprising contacting a neural cell with the compound or combination of compounds and observing the levels of DIP 1 activity, an elevated level being indicative of ability of the ability of the compound or combination of compounds to rescue neural cells from apoptosis.
4. Method according to claim 3 for monitoring the activity of a neuroactive drug or com¬ bination of neuroactive drugs in vivo.
5. A composition for rescuing neural cells from apoptosis, which composition is effective to increase the activity of DIP 1 in neural cells.
6. A method for treating a patient suffering from a neural condition comprising admini¬ stering to the patient a pharmaceutically effective amount of a composition effective to modulate the activity of DIP 1 in neural cells.
7. A compound which, when administered to a neural cell, is effective to increase the activity of DIP 1 in said cell.
8. A compound according to claim 7 selected from any one of the compounds of formula I to XXII.
9. Use of a compound in the manufacture of a composition for increasing the activity of
10. Use according to claim 9 wherein the compound is selected from any one of the com¬ pounds of formula I to XXII.
11. Nucleic acid encoding DIP 1 according to claim 1.
12. Fragment of a nucleic acid according to claim 11 comprising a functional control element.
13. Use of a DIP 1 control sequence for regulatable expression of heterologous genes.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE69635457T DE69635457D1 (en) | 1996-01-12 | 1996-12-21 | DEPRENYL INDUCED PROTEIN |
| AU13050/97A AU1305097A (en) | 1996-01-12 | 1996-12-21 | Protein induced by deprenyl$m(3) |
| US09/101,519 US6232118B1 (en) | 1996-01-12 | 1996-12-21 | Protein induced by deprenyl |
| EP96944634A EP0873406B1 (en) | 1996-01-12 | 1996-12-21 | Protein induced by deprenyl |
| AT96944634T ATE310083T1 (en) | 1996-01-12 | 1996-12-21 | DEPRENYL INDUCED PROTEIN |
| JP9524806A JP2000504211A (en) | 1996-01-12 | 1996-12-21 | Deprenyl inducible protein |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9600660.6 | 1996-01-12 | ||
| GBGB9600660.6A GB9600660D0 (en) | 1996-01-12 | 1996-01-12 | Protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1997025421A2 WO1997025421A2 (en) | 1997-07-17 |
| WO1997025421A3 WO1997025421A3 (en) | 1997-09-12 |
| WO1997025421B1 true WO1997025421B1 (en) | 1997-10-09 |
Family
ID=10786972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/005800 Ceased WO1997025421A2 (en) | 1996-01-12 | 1996-12-21 | PROTEIN INDUCED BY DEPRENYL$m(3) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6232118B1 (en) |
| EP (1) | EP0873406B1 (en) |
| JP (1) | JP2000504211A (en) |
| AT (1) | ATE310083T1 (en) |
| AU (1) | AU1305097A (en) |
| DE (1) | DE69635457D1 (en) |
| GB (1) | GB9600660D0 (en) |
| WO (1) | WO1997025421A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1105800A (en) | 1998-10-09 | 2000-05-01 | L. Sai Latha Shankar | Methods for treating multiple sclerosis |
| EP1621190A1 (en) * | 1998-10-09 | 2006-02-01 | L. Sai Latha Shankar | Deprenyl compounds for treating Multiple Sclerosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5646008A (en) * | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
-
1996
- 1996-01-12 GB GBGB9600660.6A patent/GB9600660D0/en active Pending
- 1996-12-21 JP JP9524806A patent/JP2000504211A/en not_active Ceased
- 1996-12-21 DE DE69635457T patent/DE69635457D1/en not_active Expired - Fee Related
- 1996-12-21 AU AU13050/97A patent/AU1305097A/en not_active Abandoned
- 1996-12-21 EP EP96944634A patent/EP0873406B1/en not_active Expired - Lifetime
- 1996-12-21 WO PCT/EP1996/005800 patent/WO1997025421A2/en not_active Ceased
- 1996-12-21 AT AT96944634T patent/ATE310083T1/en not_active IP Right Cessation
- 1996-12-21 US US09/101,519 patent/US6232118B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pelleymounter et al. | Characteristics of BDNF-induced weight loss | |
| EP1027440B2 (en) | Inhibitor protein of the wnt signal pathway | |
| DE69839326T2 (en) | COMPOSITIONS AND METHODS FOR MODULATING THE CELLULAR ACTIVITY OF NF-kappaB | |
| CA2114014A1 (en) | Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine | |
| CA2225185A1 (en) | Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities | |
| KR890003369A (en) | Pharmaceutical preparations | |
| DE69033937T2 (en) | Process for the production of genetic vectors for expression of the nerve growth factor in eukaryotic cells | |
| DE69637104T2 (en) | REMEDIES FOR ARTHROSIS DEFORMANS AND INFLAMMATORY JOINT DISEASES | |
| US6025193A (en) | Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression | |
| DE69830910T2 (en) | KALIUM CHANNEL PROTEINS FOR USE IN GENE THERAPY TO REDUCE ECG DYSFUNCTION | |
| US5840689A (en) | Method for stimulating the regrowth of neurons | |
| Puthuraya et al. | Effects of endogenous sugar acids on the ventromedial hypothalamic nucleus of the rat | |
| WO1997025421B1 (en) | PROTEIN INDUCED BY DEPRENYL$m(3) | |
| US20040121958A1 (en) | Methods of alleviating neuropathic pain | |
| DE69901805T2 (en) | PHARMACEUTICAL COMPOSITION WITH MUTATED TYROSIN 353 EZRIN | |
| CA2286558A1 (en) | Ngf variants | |
| US20040248984A1 (en) | Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases | |
| Wu et al. | Transsynaptic impulse activity regulates postsynaptic density molecules in developing and adult rat superior cervical ganglion. | |
| WO1993016700A1 (en) | Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and ×dema | |
| WO1998042737A3 (en) | Peptides for the treatment of systemic lupus erythematosus | |
| EP1059931B1 (en) | Utilization of cd137 in order to promote the proliferation of peripheral monocytes | |
| Fridolf et al. | Dual action of the neuropeptide galanin on the cytoplasmic free calcium concentration in RIN m5F cells | |
| JP3789147B2 (en) | Therapeutic agent for neuropathy after spinal cord injury | |
| Ebstein et al. | Beta-adrenergic-stimulated adenylate cyclase activity in normal and EBV-transformed lymphocytes | |
| DE10006887A1 (en) | Modulators of regulatory protein RS1, useful for treating diabetes or tumors and for increasing drug transport, control concentration of transport proteins in plasma membranes |